{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:50:39Z","timestamp":1781869839740,"version":"3.54.5"},"reference-count":20,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Overactive bladder (OAB) is a prevalent symptom\u2010based syndrome lacking objective diagnostic tests. Urinary biomarkers, particularly nerve growth factor (NGF), have emerged as potential non\u2010invasive tool for diagnosis and treatment monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To systematically review and meta\u2010analyze the association between urinary biomarker with treatment response and symptom score changes in adults with OAB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective clinical studies relating urinary biomarkers to established OAB treatments were identified in eight databases up to May 2024, selected with predefined criteria, assessed with the Newcastle\u2013Ottawa Scale (NOS), and synthesized as percentage mean changes; meta\u2010analysis was limited to NGF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine studies carried out NGF data and smaller subsets reported on other biomarkers, showing post\u2010treatment biomarker reductions in both responders and non\u2010responders, with greater decreases and significantly larger symptom score improvements in responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Evidence regarding the usefulness of urinary biomarkers in OAB patients is still heterogeneous and limited. Urinary NGF levels decrease during OAB treatment in accordance with symptoms questionnaires scores improvement suggesting that some urinary biomarkers may serve as a useful tool for monitoring treatment response in patients for whom symptom questionnaires cannot be administered or are considered unreliable, contributing in the differentiation of different disease phenotypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.70350","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:52:47Z","timestamp":1781866367000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Urinary Biomarkers and Response to Treatment in Overactive Bladder (OAB): A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-8694","authenticated-orcid":false,"given":"Thiago","family":"Khouri","sequence":"first","affiliation":[{"name":"Department of Urology, School of Medical Sciences University of Campinas (UNICAMP) Campinas S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Matos","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medical Sciences University of Campinas (UNICAMP) Campinas S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9768-3052","authenticated-orcid":false,"given":"Lukas","family":"Salles","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medical Sciences University of Campinas (UNICAMP) Campinas S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Mira","family":"Gon","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medical Sciences University of Campinas (UNICAMP) Campinas S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1ssio","family":"Riccetto","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medical Sciences University of Campinas (UNICAMP) Campinas S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) Joint Report on the Terminology for Female Pelvic Floor Dysfunction. Neurourol Urodyn, 2010,29:4\u201020","volume":"21","author":"Haylen B. T.","year":"2010","journal-title":"International Urogynecology J"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-012-1781-4"},{"issue":"2","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder","volume":"212","author":"Cameron A. P.","year":"2024","journal-title":"Journal of Urology"},{"issue":"1","key":"e_1_2_10_5_1","first-page":"68","article-title":"EAU Guidelines on Non\u2010Neurogenic Female LUTS (Incl. Overactive Bladder)\u2014Diagnostic Section","volume":"82","author":"Burkhard F. C.","year":"2022","journal-title":"European Urology"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.euf.2019.06.006","article-title":"Urinary Biomarkers in Overactive Bladder: Revisiting the Evidence","volume":"5","author":"Antunes\u2010Lopes T.","year":"2019","journal-title":"European Urology Focus"},{"issue":"8","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1002\/nau.24487","article-title":"The Profile of Urinary Biomarkers in Overactive Bladder","volume":"39","author":"Rada M. P.","year":"2020","journal-title":"Neurourology and Urodynamics"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page M. J.","year":"2021","journal-title":"BMJ"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-74046-7_1"},{"issue":"4","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/nau.22939","article-title":"The Use of Biomarkers in the Diagnosis and Treatment of Overactive Bladder: Can We Predict the Patients Who Will Be Resistant to Treatment?","volume":"36","author":"Alkis O.","year":"2017","journal-title":"Neurourology and Urodynamics"},{"issue":"2","key":"e_1_2_10_11_1","first-page":"140","article-title":"Nerve Growth Factor and Brain\u2010Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients With Overactive Bladder Syndrome","volume":"28","author":"Beta A.","year":"2024","journal-title":"International Neurourology Journal"},{"issue":"2","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00192-015-2825-3","article-title":"Urinary Nerve Growth Factor and a Variable Solifenacin Dosage in Patients With an Overactive Bladder","volume":"27","author":"Ciftci S.","year":"2016","journal-title":"International Urogynecology Journal"},{"issue":"8","key":"e_1_2_10_13_1","first-page":"747","article-title":"NGF and HB\u2011EGF: Potential Biomarkers That Reflect the Effects of Fesoterodine in Patients With Overactive Bladder Syndrome","volume":"34","author":"Yoo C.","year":"2015","journal-title":"Neurourology and Urodynamics"},{"issue":"7","key":"e_1_2_10_14_1","first-page":"1009","article-title":"Decrease of Urinary Nerve Growth Factor Levels After Antimuscarinic Therapy in Patients With Overactive Bladder","volume":"104","author":"Liu H. T.","year":"2009","journal-title":"BJU International"},{"issue":"6","key":"e_1_2_10_15_1","first-page":"1403","article-title":"Urinary Nerve Growth Factor Levels Are Elevated in Patients With Detrusor Overactivity and Decreased in Responders to Detrusor OnabotulinumtoxinA Injection","volume":"54","author":"Liu H. T.","year":"2008","journal-title":"European Urology"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.5152\/tud.2020.20432"},{"issue":"4","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.5213\/inj.1732794.397","article-title":"Urinary Nerve Growth Factor as a Potential Biomarker of Treatment Outcomes in Overactive Bladder Patients","volume":"21","author":"Suh Y. S.","year":"2017","journal-title":"International Neurourology Journal"},{"key":"e_1_2_10_18_1","article-title":"Role of Serum and Urinary Biomarkers in Evaluation and Management of Patients With Overactive Bladder","volume":"12","author":"Trivedi S.","year":"2019","journal-title":"Clinical Medicine Insights: Urology"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113650"},{"issue":"4","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5213\/inj.2040366.183","article-title":"Potential Role of Monocyte Chemoattractant protein\u20101 in Monitoring Disease Progression and Response to Treatment in Overactive Bladder Patients","volume":"24","author":"Ghoniem G.","year":"2020","journal-title":"International Neurourology Journal"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/02692155231225662","article-title":"Clinical Tools for Evaluating the Severity of Overactive Bladder: A Systematic Review of Psychometric Properties","volume":"38","author":"Ali M. U.","year":"2024","journal-title":"Clinical Rehabilitation"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.70350","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:52:50Z","timestamp":1781866370000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.70350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":20,"alternative-id":["10.1002\/nau.70350"],"URL":"https:\/\/doi.org\/10.1002\/nau.70350","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2026-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"nau.70350"}}